iiinova — where your digital self keeps evolving

Replies

ME/CFS Science @mecfsscience.org · 11/07/2025

2) This comes from the Norwegian team that conducted the Rituximab trials. Both are monoclonal antibodies that target markers on the surface of certain cells. Rituximab targets CD20 which is mainly found on B cells, while Daratumumab targets CD38 found on plasma cells.

170

ME/CFS Science @mecfsscience.org · 11/07/2025

3) The authors speculate that after an infection, long-lived plasma cells are producing antibodies in ME/CFS. Since these plasma cells are CD20 negative, they are not affected by (short-term) Ritxumab treatment. Hence the idea to try Daratumumab which does target these cells.

170

ME/CFS Science @mecfsscience.org · 11/07/2025

4) Four patients had no significant clinical changes, but the improvements in the other patients were quite big. SF-36 physical functioning, for example, increased from 25.9 to 55 (+29), which is bigger than for example GET/CBT in the PACE trial (+18).

160